Candriam S.C.A. Invests $3.01 Million in Replimune Group, Inc. $REPL

Candriam S.C.A. bought a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 394,027 shares of the company’s stock, valued at approximately $3,014,000.

Other hedge funds have also added to or reduced their stakes in the company. Balyasny Asset Management L.P. increased its stake in Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Replimune Group during the 4th quarter worth about $17,568,000. Commodore Capital LP bought a new position in shares of Replimune Group in the 4th quarter valued at about $13,851,000. JPMorgan Chase & Co. grew its holdings in shares of Replimune Group by 2,333.6% in the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock valued at $8,993,000 after acquiring an additional 887,157 shares in the last quarter. Finally, Toronto Dominion Bank increased its position in shares of Replimune Group by 62.5% in the fourth quarter. Toronto Dominion Bank now owns 2,229,527 shares of the company’s stock valued at $21,671,000 after acquiring an additional 857,475 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Down 0.7%

Replimune Group stock opened at $9.87 on Wednesday. The company’s 50-day moving average price is $8.31 and its two-hundred day moving average price is $7.38. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The stock has a market cap of $828.49 million, a P/E ratio of -2.92 and a beta of 0.86. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $13.24.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, analysts expect that Replimune Group, Inc. will post -2.29 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on REPL. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 2nd. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Hold” and an average target price of $8.12.

Insiders Place Their Bets

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.